Kaempferol

Kaempferol

SCHEMBL1259228

O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12.O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 1.00
KMT2A Q03164 9/20 1.00
CYP1A2 P05177 8/20 1.00
CYP3A4 P08684 8/20 1.00
ABCB1 P08183 7/20 1.00
CYP2C9 P11712 7/20 1.00
CYP1A1 P04798 7/20 1.00
CYP1B1 Q16678 7/20 1.00
KDM4E B2RXH2 7/20 1.00
FTO Q9C0B1 6/20 1.00
XDH P47989 6/20 1.00
MAPT P10636 6/20 1.00
HSD17B10 Q99714 6/20 1.00
CYP2D6 P10635 6/20 1.00
ALOX15 P16050 5/20 1.00
CYP2C19 P33261 5/20 1.00
APP P05067 5/20 1.00
TP53 P04637 5/20 1.00
ALDH1A1 P00352 5/20 1.00
HPGD P15428 5/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kaempferol SCHEMBL29378805 1.00 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL18817 1.00 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL30655455 1.00 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL34461912 0.98 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL31256029 0.98 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL30544809 0.98 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL31749037 0.98 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL31577746 0.98 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL17237761 0.98 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4ABCB1
Kaempferol SCHEMBL38651062 0.98 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023198519-A1 CROCUS SATIVUS FLOWER EXTRACTS, COMPOSITIONS COMPRISING SAME, AND USES THEREOF IN ORAL CARE ISP INVESTMENTS LLC (US) 2023-10-19 WO disclosed
CN-105301123-B A kind of HPLC detection methods of Liangfu class preparation 成都中医药大学 2017-09-29 CN disclosed
US-9040673-B2 Synthesis and identification of novel RSK-specific inhibitors UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2015-05-26 US disclosed
US-20120245112-A1 SYNTHESIS AND IDENTIFICATION OF NOVEL RSK-SPECIFIC INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-09-27 US disclosed
WO-2011019995-A2 SYNTHESIS AND IDENTIFICATION OF NOVEL RSK-SPECIFIC INHIBITORS HECHT SIDNEY M (US) 2011-02-17 WO disclosed
US-20080070971-A1 Medical Use of Bilirubin and its Structural Analogues WANG XIANG H 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070971-A1 Medical Use of Bilirubin and its Structural Analogues RBP1, RBP4, AGER MEN1 2977/4885KMT2A 4282/4885CYP1A2 82/4885
US-20120245112-A1 SYNTHESIS AND IDENTIFICATION OF NOVEL RSK-SPECIFIC INHIBITORS ULK1, RPS6KA1, RPS6KA2 MEN1 3676/4885KMT2A 2751/4885CYP1A2 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.